Healthcare Analysts, along with Dr. Wharton, a cardiologist from North Shore University Hospital, discuss the market opportunity in treating Hypertrophic Cardiomyopathy (HCM), with a focus on Camzyos (Mavacamten) by Bristol Myers Squibb (BMY), as well as the Aficamten program by Cytokinetics (CYTK) and its Phase 3 Trial (SEQUOIA) on an Analyst/Industry conference call to be held on November 20 at 1 pm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
- Aclaris Therapeutics price target lowered to $3 from $22 at Evercore ISI
- Truist biotech analyst to hold an analyst/industry conference call
- Bristol Myers Squibb call volume above normal and directionally bullish
- Bristol Myers announces FDA acceptance of sBLA for Breyanzi
- Bristol Myers initiated with a Hold at Deutsche Bank